News
Collaboration With Galapagos in AI For Drug Design
Iktos announces a collaboration deal with Galapagos, a leading global biopharmaceutical company focused on the...
Iktos & Zealand Pharma to Develop AI Technology for Peptide Drug Design
Iktos today announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with...
Collaboration with Sygnature Discovery in AI for New Drug Design
Iktos and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo drug design. Under...
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery
Iktos and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides...
Collaboration With Ono in Artificial Intelligence for New Drug Design
Iktos announces a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based...
Collaboration with Astrogen to Use AI Platform
Iktos and Astrogen have entered into a research collaboration agreement aimed at discovery of innovative small...
Collaboration with The University of Dundee to Use AI
Under the agreement, Iktos will apply its de novo ligand and structure-based generative modeling technologies, its...
Collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Iktos announces deployment of our AI for drug design software Makya™ by Jiangsu Hengrui Pharmaceuticals Co., Ltd....
Collaboration with Chiesi Group to use Makya™ for Drug Discovery
Iktos announces deployment of our AI for drug design software Makya™ by Chiesi Group. Follow the link for the full...
Collaboration with UCB in AI for Retrosynthesis
Iktos announced a software licensing agreement related to AI-based retrosynthesis analysis and planning tool Spaya™ ,...
Collaboration with Kadmon
Iktos announces that it has entered into a Research Collaboration Agreement with Kadmon, a clinical-stage...
Collaboration with Facio Therapies
Iktos and Facio Therapies announce collaboration to use AI for FSHD drug design. Follow the link for the full press...